Amryt Pharma plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amryt Pharma plc
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
With two revenue-generating products already on the market and Phase III data pending on Filsuvez for epidermolysis bullosa, CEO Joe Wiley has told Scrip that a US listing will give Amryt more visibility and credibility when it comes to future licensing and acquisition possibilities.
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
- Other Names / Subsidiaries
- Aegerion Pharmaceuticals, Inc.
- Amryt Pharma Holdings Limited
- Birken GmbH
- Birken AG